We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BioMarin Pharmaceutical Inc | NASDAQ:BMRN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.03 | -1.27% | 80.00 | 79.85 | 83.07 | 81.57 | 80.37 | 81.24 | 1,291,756 | 22:32:28 |
By Sabela Ojea
BioMarin Pharmaceutical said the Food and Drug Administration has approved its new drug application to treat all pediatric patients with a growth condition.
The biotechnology company on Friday said its Voxzogo treatment is aimed at increasing linear growth and has been approved based on an improvement in annualized growth velocity.
The medication had previously been indicated for achondroplasia patients who were 5 years of age and older.
Voxzogo is currently approved in Europe for children with achondroplasi who are at least 2 years old.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 20, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year BioMarin Pharmaceutical Chart |
1 Month BioMarin Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions